Arresting Vertical Transmission of Hepatitis B Virus

Phase 4 Completed 179 enrolled University of North Carolina, Chapel Hill Kinshasa School of Public Health · collab Ohio State University · collab

Non-randomizedSingle-groupOpen-labelPrevention

Summary

The purpose of this pilot study is to demonstrate the feasibility of adding HBV screening and treatment of pregnant women to the existing HIV PMTCT platform in order to prevent mother-to-child transmission of hepatitis B virus.

Timeline

Start: 2018-09-24
Primary completion: 2020-03-06
Completion: 2020-08-15

Publications

Thompson P, Morgan CE, Ngimbi P, Mwandagalirwa K, Ravelomanana NLR, Tabala M, Fathy M, Kawende B, Muwonga J, Misingi P, Mbendi C, Luhata C, Jhaveri R, Cloherty G, Kaba D, Yotebieng M, Parr JB. Arresting vertical transmission of hepatitis B virus (AVERT-HBV) in pregnant women and their neonates in the Democratic Republic of the Congo: a feasibility study. Lancet Glob Health. 2021 Nov;9(11):e1600-e1609. doi: 10.1016/S2214-109X(21)00304-1. Epub 2021 Aug 17.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Engerix-B	Vaccine	0.5 ml	—
Subject	Tenofovir disoproxil fumarate	Small molecule	300 mg	Oral

Arresting Vertical Transmission of Hepatitis B Virus

Summary

Timeline

Publications

Drugs

Indications